Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Klastersky, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Klastersky, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 5:641-643, 1994
© 1994 European Society for Medical Oncology

brief-report

A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5-fluorouracil

A regimen associated with major toxicity in patients with advanced non-small cell lung cancer

J. Klastersky, J. P. Sculier, F. Ries, G. Dabouis, P. Libert, J. Schmerber, J. Thiriaux, M. C. Berchier, G. Bureau, O. Van Cutsem, A. Tagnon, R. Sergysels, P. Mommen, M. Paesmans and For the European Lung Cancer Working Party*

Correspondence to: Prof. J. Klastersky, Service de Médecine, Institut Jules Bordet, 1, rue Héger Bordet, B-1000 Bruxelles, Belgium

PURPOSE:: To determine in patients with advanced non-small cell lung cancer the activity of a 4-drug combination chemotherapy.

PATIENTS AND METHODS:: Chemotherapy consisted of the administration of cisplatin (30 mg/m2 d 1–3 or 4), mitomycin C (10 mg/m2 d 1), vindesine (3 mg/m2 d 1) and 5-FU (1 g/m2 d 1–3 or 4 by continuous intravenous infusion.

RESULTS:: 182 were eligible patients. A 34% objective response rate was observed in the 164 evaluable patients. The overall median survival was 26 weeks. The most serious adverse event was the occurrence of 18 (10%) cardiac or sudden deaths. These toxic deaths were significantly associated with a ≥ 5% loss of body weight prior to therapy.

CONCLUSIONS:: The regimen studied resulted in a very significant cardiac toxicity.

cardiac toxicity, chemotherapy, non-small cell lung cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.